Streptococcus agalactiae, or Lancefield group B streptococcus (GBS), is the most frequent cause of serious bacterial sepsis, including neonatal meningitis, in UK neonates. Early-onset neonatal GBS infection, but not late-onset, can be prevented by screening to identify high-risk pregnancies and administering penicillin during delivery. A vaccine has been developed as an alternative means of prevention but it is awaiting a randomized trial before being available for general use. In this review we examine the published literature to assess the morbidity and mortality attributable to neonatal GBS infection, quantify the screening performance of the two alternative modes of screening (microbiological and risk factor based), review the evidence on the efficacy of the vaccine, and estimate the numbers of deaths and cases of serious disability that each strategy in turn might prevent in the UK, in order to assess the most effective means of prevention for the UK.
INTRODUCTION
S treptococcus agalactiae, or Lancefield group B streptococcus (GBS), is a major cause of invasive disease at all ages 1 and is the most frequent cause of serious bacterial sepsis, including neonatal meningitis, in UK neonates. 2, 3 Originally a predominantly bovine pathogen, GBS emerged as a serious human pathogen quite suddenly in the 1970 s (transference of virulence genes, possibly from group A streptococcus, is one possible explanation for its sudden emergence 4 ).
Early-onset neonatal GBS infection (though not late-onset) can be prevented by screening to identify high-risk pregnancies and administering penicillin during delivery (intrapartum 5 ), but there is a striking difference in policy in this respect between the USA and the UK. In the USA, screening in pregnancy is recommended by specialist medical organizations and is widely practiced 5 (this is also the case in Australia 6,7 ). In the UK, and in many European countries, screening is not recommended 8 or practiced, 9 and only scanty risk factor based screening is performed. A vaccine has been developed as an alternative means of prevention but it is awaiting a randomized trial before being available for general use.
In this review we examine the published literature to assess the morbidity and mortality attributable to neonatal GBS infection, quantify the screening performance of the two alternative modes of screening (microbiological and risk factor based), review the evidence on the efficacy of the vaccine, and estimate the numbers of deaths and cases of serious disability that each strategy in turn might prevent in the UK, in order to assess the most effective means of prevention for the UK.
PREVALENCE AND ATTRIBUTABLE MORTALITY AND MORBIDITY Early-and late-onset disease
Early-onset disease is generally defined as infection in the neonate occurring 0-6 days after birth, though 90% of cases present less than 24 h after birth. It is due to vertical transmission from the mother. Colonization (the presence of organisms on the skin and mucous membranes) of the lower vagina by GBS is common and generally asymptomatic, the lower gastro-intestinal tract being the reservoir. Colonization of the neonate takes place during passage through the vagina at birth (accordingly, colonization is rare in neonates delivered by Caesarean section before the onset of labour 10 ). Once colonization of the neonate is established, systemic infection may occur via the umbilical cord, the respiratory tract or skin abrasions. A second important source of infection, occurring before birth, is the ascent of organisms to the fetus from the mother's genital tract through ruptured or intact membranes, with aspiration or ingestion of infected amniotic fluid by the fetus. Hence prolonged rupture of the membranes is a risk factor, and GBS infection may cause premature delivery, stillbirth or disease that the baby is born with. The infection in the neonate is septicaemia (with or without osteomyelitis, septic arthritis or other focal infection [63% of cases in the UK]), pneumonia (26%), meningitis (11%) or, rarely, focal infection (0.6% 11 ).
Late-onset disease is generally defined as infection in the neonate occurring seven or more days after birth; it may occur up to 90 days after birth and hence extend beyond the neonatal period as strictly defined. Late-onset disease is mostly due to horizontal transmission (often from the mother). Intrapartum antibiotics cannot prevent it, though vaccination could. The infection is meningitis (43%), septicaemia (41%), pneumonia (8%) or focal infection (7% 11 ). Importantly, meningitis is more common in lateonset than early-onset disease. 15 In the UK, prevalence can be determined from the 'national study' that identified all cases of neonatal GBS disease in the UK and the Republic of Ireland (from 1 February 2000 to 28 February 2001 11 ). The prevalence was 0.48 per 1000 births for early-onset disease and 0.24 per 1000 births for late-onset disease. Smaller studies conducted in various localities within the UK have shown similar prevalence. [16] [17] [18] [19] [20] The explanation for the difference in early-onset disease between the USA (2.0 cases per 1000 before antibiotic prophylaxis) and the UK (0.5 per 1000), when antibiotic prophylaxis is rarely used in the UK, 9 is not certain. Underestimation in the UK (see below) is one factor. Another possible reason is a lower prevalence of vaginal GBS colonization in the mother. The only published UK prevalence estimate was 28%, 21 but this was 18 years ago and from a high-risk area (the prevalence of vaginal GBS colonization varies considerably between communities 12 ). Recent unpublished data from a small study at St George's Hospital, London, showed a prevalence of 12% (P Heath, personal communication).
The prevalence of early-onset disease in the UK of 0.48 per 1000 is equivalent to 325 cases per year, with 10% (33) fatal. 11 The number of cases is underestimated, however, for two reasons. First, there is under-reporting: a capture/ recapture analysis in the national study indicated an extra 23% of cases. 11 Hence we might expect 400 cases (325 Â 1.23, or 0.6 per 1000) and 40 deaths per year in the UK. Second, an infection is attributed to GBS only when there is a positive culture from a normally sterile site (e.g. blood or cerebrospinal fluid). Most neonatal sepsis is presumed and not culture proven, and if GBS disease was defined as clinical signs of sepsis plus a positive culture from a surface swab there would be 2-3 times more cases of earlyonset disease. 16, 22 The second of these two sources of underestimation will also affect estimates from the USA, but not the under-reporting as the USA has a 100% case ascertainment system through active surveillance. The under-diagnosis in the UK tends to involve cases of relatively mild severity; the underestimation of fatal cases was smaller. 16 The best estimate may be 40-45 deaths from early-onset disease per year in the UK.
Case fatality of early-onset disease differs between the USA (4-6%) and the UK (10%). This may occur partly because the under-estimation in the UK predominantly involves milder cases, as outlined above, and partly because early-onset disease is more often fatal in babies born preterm; early-onset disease is more commonly associated with prematurity in the UK than in the USA. When neonatal GBS infection first appeared in the 1970s, case fatality was as high as 50% in the USA: the 90% decline is attributed to ongoing advances in neonatal care, 5 but there is no evidence that the difference in case fatality reflects more effective treatment of neonatal GBS infection in the USA than the UK.
Compared with early-onset disease, the difference in prevalence of late-onset disease between the USA (0.35 per 1000 14 ) and the UK (0.24 per 1000 11 ) is small, and there has been relatively little change over time in its prevalence. There are about 160 late-onset cases per year in the UK, with 8% (13) fatal, 11 or about 200 cases and 16 deaths per year after adjusting for the underestimation.
Morbidity
In the national study, 11% of the neonates with early-onset disease and 43% with late-onset disease had GBS meningitis. 11 In another study of 98 children who developed GBS meningitis in the first year of life and were followed to age five, half had residual disability. 3 Therefore about 5% (half of 11%) of infants with early-onset disease, or 17 per year in the UK (5% of 325), would have long-term disability (including mental retardation and visual loss) resulting from meningitis. From similar calculations, 21% of infants with late-onset disease -or about 35 per year in the UK -would have long-term disability from meningitis. Disability can also be expected from cerebral palsy (associated with neonatal sepsis) and from other causes; cerebral perfusion may be altered by shock resulting from sepsis. Based on the national study, around 25 early-onset GBS-infected neonates (7% of the total) have disability on discharge from hospital in the UK each year, 11 though some of this may have occurred anyway because of the associated prematurity. About 40 per year may have long-term disability from late-onset disease.
In summary, allowing for underestimation, in the UK each year there are probably 40-45 neonatal deaths and about 25 cases of long-term disability caused by early-onset GBS disease, and about 16 deaths and 40 cases of disability from late-onset GBS disease. Importantly, while less common than early-onset disease, late-onset disease accounts for more morbidity because a higher proportion of late-onset cases are meningitis.
SCREENING AS A MEANS OF PREVENTION Risk factors for early-onset GBS infection
Several risk factors for early-onset GBS infection can be used as screening markers in identifying high-risk women (risk factor-based screening). The three most important are prolonged rupture of the membranes (X18 h), pre-term onset of labour (o37 weeks) and maternal fever (X381C) during delivery (GBS can cause intrapartum ascending genital tract infection 23 ). Two other risk factors are associated with relatively few cases in the UK: a previous baby with GBS infection, and known genital carriage of GBS, which in the absence of routine microbiological screening, as in the UK, will be detected only through GBS bactiuria identified during the pregnancy or incidental identification in vaginal swabs done for other purposes. Table 1 summarizes the prevalence of these risk factors in pregnancies in which the neonate developed early-onset GBS infection (the detection rate if they were used as screening markers), in seven UK studies. The first three risk factors identified 45%, 37% and 19% of cases, respectively. The presence of any one or more of these five risk factors identified 67% of cases (from six of the studies). In the national study, which did not record maternal fever or a previous GBS-infected infant, one or more of the other three was present in 58% of cases. 11 The proportion of deaths positive on risk factor-based screening was higher (73% in the national study 11 ). Table 2 shows the prevalence of these risk factors in unaffected pregnancies (the false-positive rate if they were used as screening markers), in three UK studies. Overall, one or more of the risk factors was present in 17% of unaffected pregnancies. In Table 3 , the likelihood ratio associated with each of the five risk factors is shown: this can be calculated simply as the detection rate divided by the false-positive rate. The likelihood ratio is the 'concentrating power' of the risk factor: when multiplied by the background risk (0.6 per 1000 or 6:9994 in the UK), it provides an estimate of the risk of early-onset GBS disease in pregnancies in which the risk factor is present. On average, UK women with one or more of the risk factors account for 67% of all cases (detection rate 67%) and 17% of all unaffected pregnancies (false-positive rate 17%), and the odds of their baby being infected with GBS are about 1:420 (2.4 per 1000).
Associations of GBS colonization with social class, young maternal age and ethnicity exist; 5,18 they will contribute to the variation in prevalence of infection across different communities, but they are too weak for use in screening.
Microbiological procedures in detecting GBS colonization
Detecting vaginal GBS colonization of pregnant women is an alternative means of identifying high-risk women in relation to early-onset GBS infection. Because colonization is intermittent, the earlier in pregnancy a swab is done the less it is predictive of vaginal carriage at birth. On the other hand, later swabs will miss pre-term births. Taking swabs during weeks 35-37 of pregnancy is the generally recommended compromise, but it will miss late colonization. Both the lower vagina and ano-rectal area should be swabbed. Isolation of GBS from swabs taken from these areas requires the use of selective enrichment culture medium; 23 the standard method for culturing swabs for GBS in the UK does not do this and detects only about half of colonized women. Whether the undetected cases are at similar risk of causing infection in the neonate has never been shown (less intense maternal colonization is associated with a lower risk of infant colonization 24 ), but it is generally considered reasonable to assume that they are and that the standard culture method is therefore inappropriate for detecting carriage. The 'gold standard' test is not routinely used in the NHS and would cost about £20 per test. There are nine different GBS serotypes based on capsular polysaccharide antigens. Five of these (Ia, Ib, II, III and V) cause nearly all cases of neonatal GBS infection. 25, 26 Intrapartum penicillin prophylaxis GBS is (at present) always sensitive to penicillin. Recommended treatment to prevent neonatal infection is penicillin 3 g intravenously as soon as possible after the onset of labour and 1.5 g four-hourly until delivery. It is generally recommended that the first dose should be at least 4 h before birth, though there is little direct evidence on this; a shorter time may be sufficient. 27 Clindamycin or cefazolin is used in women allergic to penicillin. Trans-placental passage of the antibiotic before birth and reduction of the density of GBS colonization of the birth canal are mechanisms of action. The alternative policy of administering the antibiotic directly to the neonate after birth (rather than during labour) has disadvantages: the infection may develop either before birth or soon after, so the later attainment of maximal serum and tissue concentrations of penicillin with administration after birth would be expected to be less efficacious. Also, an injection into the cord may cause thrombosis.
Five published randomized controlled trials of intrapartum penicillin or ampicillin to women with known GBS vaginal colonization, 28, 29 conducted in the 1980s, demonstrated substantial reductions in colonization and infection in the neonate. The results of these trials, with summary odds ratios, are shown in Table 4 . The trials show large and statistically highly significant reductions in GBS colonization (10 versus 140 cases) and GBS bacteraemia or septicaemia (0 versus 14 cases). These randomized trials have been criticized because of 'potential selection bias' 28 as the detection of bacteraemia was based not on routine blood culture at delivery in all infants but on cultures from selected infants according to 'clinical indications' 32, 34 in two trials, and this may have been influenced by the knowledge of which infants had received intrapartum antibiotics (the trials were not blind). However, the two trials that did detect bacteraemia from routine cultures on all infants are conclusive on their own. 31, 33 Also, the surrogate marker of colonization was based on routine cultures in all four trials. The trials confirm that the intervention is effective.
Screening
There are two main screening strategies to identify high-risk women to be given intrapartum penicillin. 35 Estimates of screening performance are summarized in Table 5 .
Risk factor-based screening
Women with one or more of the five risk factors (Tables 1-3 ) are deemed to be high-risk and are given intrapartum penicillin. No microbiological cultures are performed. From Tables 1-3, this strategy detects an estimated 67% of cases and, as treatment is not invariably effective, will prevent about 60% of cases. The false-positive rate is about 17%. Among women with any one or more of the five markers, the odds of a GBS-infected infant are 1:420 on average. However, broader spectrum oral antibiotic prophylaxis should be given routinely to women with pre-term rupture of the membranes in any case, because it prolongs pregnancy and reduces all-cause neonatal sepsis. 36 Whether intravenous penicillin needs to be given as well, because either the broader spectrum antibiotics or the oral route of administration is less effective against GBS sepsis, is uncertain.
Microbiological screening
Low vaginal and peri-anal swabs are taken at 35-37 weeks from all women to detect GBS colonization. If labour commences before the swab is taken at 35-37 weeks, the woman will receive treatment (hence this strategy is at present partly risk factor-based, though the availability of a rapid near-patient test 13, 37 could avoid the need for this). This strategy prevents about 90% of cases. The positive rate in the UK is the proportion of premature deliveries (6% in the UK, from A cohort study based on data from obstetric units in eight 'active surveillance' sites in the USA confirmed the substantially greater effectiveness of microbiological screening than risk factor-based screening 38 and led to recommendations for its routine use in the USA. 5 A combination screening approach has also been suggested: only women positive on both methods (microbiological and risk factor-based) would be treated, except that all women who go into labour before the swab is taken at 35-37 weeks are treated. This strategy would prevent only slightly fewer cases than risk factor-based screening (about 55%), as almost all cases prevented by risk factor-based screening would have been microbiologically positive had testing been done. The positive rate would be the proportion of births that are preterm (6%) plus the proportion of term pregnancies positive on one or more other risk factors and colonized (2%), about 8% overall. The combined approach is unsatisfactory. Compared with risk factor-based screening alone, the small reduction in the positive rate would not justify the cost of microbiological testing of all women, and compared with microbiological screening alone, the reduction in the positive rate does not warrant the loss of detection.
Neither form of screening can prevent late-onset GBS infection, as intrapartum penicillin will not prevent infection occurring a week or more later.
Screening (either risk factor-based or microbiological) with intrapartum antibiotic prophylaxis has been widespread in the USA since about 1996, following recommendations by the American Academy of Pediatrics, 39 the American College of Obstetricians and Gynecologists, and the CDC. 5 This was associated with a 70% decrease in the prevalence of early-onset neonatal infections, from 1.7 per 1000 live births in 1993 to 0.5 per 1000 in 1999. 5 Following a recommendation in 2002 for all screening to be microbiological 5 and an increase in the uptake of screening to over 90%, the prevalence of early-onset neonatal infections has fallen further, to 0.3 per 1000 (an 82% decrease). Over the same period, there was no significant decrease in other neonatal infections, and for this and other reasons the decline in early-onset infections was attributable to the screening rather than more general factors. 5,40,41 A comparable decline in early-onset disease following screening has been seen in Australia. 6, 7 Potential harm from intrapartum penicillin prophylaxis Three possible hazards from intrapartum penicillin prophylaxis have been claimed.
Fatal maternal anaphylaxis caused by penicillin allergy
It has been stated in reviews that death occurs in 1 in 100,000 treated women, 8 but the source of this estimate is not apparent and it is likely to be an overestimate. If true, this would mean that implementing screening would on average cause the death of two mothers each year in the UK. American data, however, indicate that fatal anaphylaxis is much less common than this. Table 6 shows statistics each year from 1979 to 2001 on the numbers of deaths in the USA caused by penicillin administered in a hospital to women aged 18-44, which will include, but not be limited to, deaths from intrapartum penicillin prophylaxis (see Acknowledgements for the source of these data). There are about four million births per year. Over the five years 1997-2001, at least half of the 20 million pregnant women were screened for GBS colonization, 20% of these were found to be colonized, and 90% of those colonized were given antibiotics, 5 so at least 1.8 million women will have been given penicillin (or ampicillin). If death occurred in one per 100,000, we would expect 18 deaths over the five years, and if death occurred in one per million, we would expect two. In fact, no deaths occurred. In a review of 1225 hospital admissions in Britain related to adverse drug reactions, in a population of 630,000 over six months, none were due to penicillin, 42 again indicating that severe reactions are rare. It can be concluded that the risk of death is negligible.
Rashes and other non-fatal manifestations of penicillin allergy will of course occur, while other mothers (and infants) will be sensitized such that they may develop an allergic reaction the next time they are given penicillin. The prevalence of such complications is difficult to quantify.
Increased risk to the infant of allergic reactions in later life
Increased risk to the infant of allergic reactions in later life has been inferred 8 based on evidence summarized by Murch 43 that 'specific input from the faecal flora to the innate immune system is essential for the establishment and maintenance of mucosal immune tolerance', and assuming that penicillin during labour would disrupt this. This is speculative. Penicillin is not a broad-spectrum antibiotic and, in any event, the faecal flora only become established a few days after birth. There are no data to support infant sensitization.
Problems arising from the elimination of penicillin-sensitive organisms
Problems arising from the elimination of penicillin-sensitive organisms are a significant theoretical hazard. 'Selection pressure' may lead to the overgrowth of penicillin-resistant pathogens (such as Gram-negative enterobacteria) that are associated with higher neonatal mortality, or to the development of resistance in other pathogens (such as ampicillin-resistant Escherichia coli 24, 36, 44 ). In the USA, GBS isolates with confirmed resistance to penicillin have not been observed to date. 5 Monitoring of antibiotic sensitivities will continue indefinitely.
Screening in the UK
At present, screening is scarcely practised in the UK. In a survey of all 249 obstetric units in the UK in 2001 (203 responded 9 ), routine swab-based microbiological screening was carried out in only 2% of units. The extent of risk factor-based screening was also limited; almost all units (95%) offered intrapartum antibiotics to known GBS carriers and women with a previous GBS-infected baby, but these are the two weakest risk factors, detecting only about 6% of cases between them ( Table 1 ). The three stronger risk factors were utilized in screening in 1-4% of units.
There are disadvantages to the routine use of microbiological screening in the UK, despite the fact that it is more effective than risk factor-based screening. The central issue is that early-onset disease is only a quarter as common in the UK as it was in the USA before the introduction of screening and intrapartum antibiotics. Hence, the gain in absolute terms is only a quarter as great. The case that the prevention of the disease outweighs the disadvantages is stronger in the USA than in the UK.
The disadvantages are:
Cost: The microbiological culture (requiring enrichment broth) costs about £20 per case in the UK, and while this might fall with widespread use, the immediate cost of screening the 735,000 pregnant women per year 11 in the UK would be £14.7 million, or about £250,000 per death or case of disability prevented if screening were 90% effective. Given that risk factor-based screening could prevent 60% of the cases without incurring this cost, the marginal cost of microbiological screening to detect the additional 30% is three times as great -about £750,000 per death or case of disability prevented. Microbiological screening would also consume the time of the obstetrician with the need for explanation and counselling with respect to the possibility of GBS infection in a baby, as well as clinic time and laboratory time.
Need to update systems: The 35-37-week swab would typically be taken from a community clinic and the result returned there; obtaining the result in the labour ward out of hours and at short notice would require the setting up of a system of either electronic reporting of laboratory results or transmission of laboratory results to labour wards.
Intrusiveness: There is a perceived importance in the UK of avoiding 'medicalization' of childbirth -some women would prefer not to have an intravenous cannula in place, for example. Also, both a vaginal and an ano-rectal swab are necessary, and these are intrusive (though data from the USA suggest that women may take their own swab as effectively as their physicians do).
Risk factor-based screening avoids these problems. While avoiding the costs, intrusiveness and problems of communicating results associated with microbiological screening, however, it prevents only 60% of cases.
The development of a rapid (45 min) test for maternal colonization 13, 37, 45 could change the UK preference because it allows the identification of vaginal colonization at the time of delivery, either in all women or in women with risk factors. This is not yet the case, however, because the available tests are no less costly than culture-based testing and because they require a technician (hence maternity units would require on-call technicians 24 h a day to be added to their staff 45 ). A rapid test that could be used simply by the midwife is under development. The rapid tests have the disadvantage that they cannot determine antibiotic sensitivity (needed for women allergic to penicillin).
VACCINATION AS A MEANS OF PREVENTION
There is an alternative to screening: the vaccination of women during or before pregnancy could prevent neonatal GBS infection by transplacental transfer of protective IgG antibodies. 4, 5, [46] [47] [48] [49] If effective, vaccination would have substantial advantages over both risk factor-based and microbiological screening. It could prevent late-onset GBS disease as well as early-onset disease in the infant, prevent pre-term labour and stillbirth caused by GBS infection, prevent intrapartum and post-partum GBS ascending genital tract infection in the mother, and avoid allergic reactions to penicillin and concerns about the emergence of antibiotic-resistant bacteria.
The GBS vaccine
GBS has capsular polysaccharide antigens (the basis of the different serotypes). Several case-control studies have shown that GBS-colonized mothers whose infants developed early-onset GBS infection had, on average, lower (or undetectable) levels of serotype-specific IgG antibody than colonized mothers whose infants remained well. 4, [46] [47] [48] 50 Also, the infected infants themselves had lower levels of IgG than infants who remained well. These and other studies established that substantial maternal levels of serotypespecific IgG antibody will protect neonates against invasive disease, but that most women of childbearing age do not have sufficient levels of these antibodies, 46, 47, 50 an ideal background for the development of a vaccine.
The first capsular polysaccharide vaccines proved to be poorly immunogenic (only 50% of subjects showing significant increases in antibody levels 4, 51 ). Trials of protein conjugate vaccines followed, using tetanus toxoid as the conjugate (in view of its earlier success in the Haemophilus influenzae type b vaccine 49 ). Trials of these GBS vaccines showed that they were safe, well tolerated and immunogenic, producing increases in antibody to protective levels known to prevent disease in 90% of subjects. 4, 49, 52, 53 The antibody response was observed to persist for over a year in the mother and the passive protection in the neonate persisted for at least three months, hence it would be expected to protect against late-onset disease. 4, 48, 50, 54 Moreover, the IgG antibody is bactericidal. 4 At present, a fully effective vaccine should be pentavalent, so as to induce antibodies against all five GBS serotypes that cause disease (see section on Microbiological procedures in detecting GBS colonization), but a univalent GBS vaccine active against a single surface protein shared by the five serotypes is under development. These studies indicate that a GBS conjugate vaccine given in a single dose, perhaps at around 26 weeks gestation, would be expected to be safe and highly effective, preventing about 90% of early-onset and late-onset GBS infections. 4 The further development of the GBS vaccines There is need for a larger, randomized trial recording neonatal disease events (phase 3), but there are two issues. First, the risk of litigation makes the pharmaceutical industry reluctant to develop any product to be used during pregnancy. 4 This is the case despite the fact that the risk of teratogenicity from a GBS conjugate vaccine is negligible; tetanus toxoid (the conjugate protein) has been given to millions of pregnant women in developing countries without adverse effects and it is difficult to imagine how conjugating it with a polysaccharide could make it harmful to the fetus. 4 Nonetheless, it is likely that a 'no fault' compensation scheme would need to be devised before a trial in pregnant women could proceed. In the longer term it may be possible to give the vaccine to adolescent schoolgirls, but it would be necessary as a first step to administer the vaccine in pregnancy and show its effectiveness, and subsequently to show that the antibodies persisted for two or three decades when given to adolescents.
The second issue is that screening and intrapartum penicillin has greatly reduced the prevalence of infection in the USA, while prevalence is already low in the UK and other countries. This may reduce the perceived need for a vaccine such that a commercial sponsor may judge that it would not be cost-effective to develop it.
Conducting a trial
It would be difficult to conduct a randomized trial of the vaccine with a reduction in neonatal sepsis as the endpoint in the USA because early-onset disease has been virtually eliminated by screening and it may be judged unethical to suspend the programme. The UK, with virtually no screening in place at the moment, would be a suitable location. The prevalence of early-or late-onset sepsis is 0.72 per 1000 live births 11 and sample size calculations indicate that, if the vaccine were 90% effective, a randomized trial would require 18,000 participants in the vaccine arm and 18,000 controls (36,000 altogether; about 5% of all the pregnancies in the UK in a year) for an 80% probability of showing a statistically significant (Po5%) reduction in GBS-infected infants. A UK trial of vaccination versus no screening or other intervention (apart from the minimal degree of screening already taking place) should be realistic if conducted soon, before screening becomes more widespread. A cluster design (randomizing maternity units rather than individual women to vaccine or control) may be appropriate.
A randomized trial intended to directly compare vaccination with risk factor-based screening would probably be prohibitively large. Only early-onset disease (0.5 per 1000) could be the endpoint, and a trial would require 67,500 in each arm (135,000 together -about 20% of all pregnancies in the UK in a year).
If it were problematic to conduct a trial of vaccine versus no vaccine during pregnancy (through fear of teratogenicity, however unfounded), the trial would need to recruit women likely to become pregnant in the next 1-2 years. The best way to recruit such women in large numbers may be to identify women at the time of their first childbirth. Alternatively (though less desirably), surrogate immunological measures of clinical efficacy based on maternal and neonatal serotype-specific IgG antibody may be sufficient endpoints. 25, 48 RECOMMENDATIONS What is the best preventive strategy for the UK? Table 7 summarizes estimates of the numbers of deaths and cases of serious disability estimated to be prevented by each of the three preventive strategies. Of the 40 or so deaths and 25 cases of serious disability from early-onset GBS in the UK each year, risk factor-based screening would be expected to prevent 60% (24 deaths and 15 cases with disability), and microbiological screening 90% (36 deaths and 23 cases of serious disability). Neither would prevent late-onset disease. Vaccination could prevent about 90% of both early-onset and late-onset of disease, an advantage because disability (particularly following meningitis) complicates late-onset disease more often than early-onset disease. Vaccination would prevent an estimated 50 deaths and 59 cases of serious disability per year in the UK. A new prevention programme is warranted if it can prevent 109 deaths or cases of serious disability in neonates per year -prevention strategies are already in place in the UK for congenital syphilis (15 cases per year), phenylketonuria (75 cases per year) and congenital hypothyroidism (220 cases 55 ). GBS vaccination would also prevent pre-term labour and stillbirth caused by GBS infection, prevent post-partum GBS infection in the mother, and avoid allergic reactions to penicillin and concern about the emergence of antibiotic resistant bacteria. Moreover, there are no indications of hazard.
Research priorities

High priority
A randomized trial of the GBS vaccine recording disease endpoints as outlined above is by far the most pressing need in this field. Funding for such a trial should be a high priority in the UK. ................
Moderate priority
The prevalence of GBS colonization in pregnant women in the UK is uncertain; a small study based on cultures from successive pregnancies in several locations in the UK would answer this. A rapid (45 min) test to identify colonization that was suitable for use in the labour ward (inexpensive and able to be used by the midwife) would be an important development that could counter the perceived disadvantages of microbiological screening in the UK.
Not a priority
Randomized trials testing screening-based interventions are not priorities. There is a common but nevertheless misguided view in the UK that it is uncertain whether GBS screening does more good than harm, 8 but this is established beyond reasonable doubt. The data on screening performance in the UK (Tables 1-3 ) are secure, the randomized trials summarized in Table 4 establish that intrapartum antibiotics substantially reduce early-onset infection in the neonate, and the risk of penicillin causing death or serious illness in the mother or the infant is negligible (see section on Potential harm from intra-partum penicillin prophylaxis). The necessary trials would in any case be prohibitively large. To show a statistically significant (Po5%) difference between risk factor-based screening (expected 60% reduction in early-onset sepsis; prevalence 0.5 per 1000) and no screening at 80% power would require 136,000 participants, and to show a statistically significant difference between microbiological and risk factor-based screening would require 200,000; either would be by far the largest randomized trial ever conducted. The cost would in no way be justified.
Conclusions
Vaccination against GBS is potentially the most effective method of preventing the morbidity and mortality caused by the infection. It has the potential to prevent about twice as many cases of death and disability in the neonate as microbiological screening, and three times as many as risk factor-based screening. A large randomized trial should be carried out to properly assess this.
